Comparative Pharmacology
Head-to-head clinical analysis: OPCON A versus ZYRTEC D 12 HOUR.
Peer-Reviewed Evidence
Head-to-head clinical analysis: OPCON A versus ZYRTEC D 12 HOUR.
OPCON-A vs ZYRTEC-D 12 HOUR
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Synthetic vasopressin analog; stimulates V1 receptors on vascular smooth muscle causing vasoconstriction, and V2 receptors in renal collecting ducts increasing water reabsorption.
Cetirizine is a second-generation antihistamine that selectively inhibits peripheral H1 receptors, reducing histamine-mediated allergic responses. Pseudoephedrine is a sympathomimetic amine that acts as a decongestant via alpha-adrenergic receptor agonism in the respiratory tract mucosa, causing vasoconstriction and reduced edema.
0.1% ophthalmic solution: 1 drop in the affected eye(s) every 3-4 hours as needed for redness relief.
1 tablet (5 mg cetirizine / 120 mg pseudoephedrine) orally every 12 hours. Maximum 2 tablets per 24 hours.
None Documented
None Documented
Terminal elimination half-life is approximately 2-4 hours in healthy adults; may be prolonged in renal impairment.
Cetirizine: 8-10 hours in healthy adults; increased in renal impairment (e.g., up to 30 hours in severe impairment). Pseudoephedrine: 5-8 hours (pH-dependent; longer in alkaline urine).
Primarily renal excretion of unchanged drug and metabolites; about 70-80% of the dose eliminated via urine within 24 hours, with 10-20% fecal elimination.
Cetirizine: 70% renal (unchanged), 10% fecal. Pseudoephedrine: 90% renal (unchanged), remainder metabolized and excreted in urine.
Category C
Category C
Ophthalmic Antihistamine/Decongestant Combination
Antihistamine and Decongestant Combination